血管紧张素转换酶抑制剂对血透患者促红细胞生成素浓度的影响  

Effect of Angiotensin-converting Enzyme Inhibitor on Serum Levels of Erythropoietin in Patients with Hemodialysis

作　　者：周盾[1] 贾艳秋[1] 孙洞箫[1] 冯欣[1] 

机构地区：[1]锦州医学院附属第一医院肾内科,锦州121000

出　　处：《中国临床医学》2005年第5期842-843,共2页Chinese Journal of Clinical Medicine

摘　　要：目的：探讨血管紧张素转换酶抑制剂对血透患者促红细胞生成素浓度的影响及可能的机制。方法：分别把接受促血细胞生成 素(EPO)治疗的16例血透患者与不接受 EPO 治疗的9例血透患者进行随机分组，实验组给予血管紧张素转换酶抑制剂(ACEI)降压 治疗，对照组则给予钙通道阻滞剂或加用α-受体阻滞剂治疗。治疗前及6个月后分别测定 EPO 浓度及血红蛋白(Hb)水平。结果： 应用 ACEI 组 Hb 及血清 EPO 浓度明显下降。结论：ACEI 可导致血透患者 EPO 浓度及 Hb 水平的下降，影响 EPO 的疗效。Objective：To assess the effect of angiotensin-converting enzyme inhibitors （ACEI） on the serum level of erythropoietin （EPO） in patients receiving hemodialysis and explore the possible mechanism. Methods ：Twenty-five patients receiving hemodialysis were enrolled in this study, 16 patients received EPO treatment while 9 patients did not receive EPO theraphy, the 2 groups were randomly sub divided into treatment group and control group. The treatment groups were was given ACEI antihypertensive therapy while the untrol groups were siven calcium channel blocker or a-receptor blocker. Serum levels of EPO and hemoglobin（Hb） in all the patients were measured before and 6 months later. Results： The serum levels of EPO and Hb decreased significantly in the treatment group （P〈0. 05）. Conclusion ：ACEI may decrease the serum EPO and Hb levels in patients receiving hemodialysis.

关 键 词：促红细胞生成素 血管紧张素转换抑制剂 血液透析 

分 类 号：R459.5[医药卫生—治疗学]